43 Stories, most recent news story added Tue Dec 8, 5:25 pm ET
Blood vessel blockage, a common condition in old age or diabetes, leads to low blood flow and results in low oxygen, which can kill cells and tissues. Such blockages can require amputation resulting in loss of limbs. Now, using mice as their model, researchers have developed therapies that increase blood flow, improve movement and decrease tissue death and the need for amputation.
Blood vessel blockage, a common condition in old age or diabetes, leads to low blood flow and results in low oxygen, which can kill cells and tissues. Such blockages can require amputation resulting in loss of limbs. Now, using mice as their model, researchers have developed therapies that increase blood flow, improve movement and decrease tissue death and the need for amputation.
Something might be up, but it's not John Otto's bank account. The former patient of Dr. Arnold Melman, a world-renowned erectile dysfunction expert, says he lost $1 million investing in a gene therapy company recommended by the man-doc.
The standard treatment for venous leg ulcers, lower limb compression, takes up to six months to heal and is unsuccessful in 30 -70 percent of cases. The new treatment involved injecting venous leg ulcers with a non-replicating adenovirus that expresses platelet-derived growth factor-β (PDGF-β).
Gamida Cell announced today a feasibility study evaluating the preclinical safety and efficacy of a gene therapy product which combines technology from Weill Cornell Medical College and Gamida Cell.
AMSTERDAM, December 2 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today a number of management changes.
Reportlinker.com announces that a new market research report is available in its catalogue:
The facility consists of a two-story administrative wing and a three-story research wing, set to seek certification from the US Green Building Council’s Leadership in Energy and Environmental Design or LEED program.
After years of complications and high-profile setbacks, a series of small but intriguing advances has suggested that gene therapy may hold real future potential for treatment
Image Caption: This image shows the effect of gene therapy combined with cytotoxic agents in E spheroids derived from breast cancer cell line MCF-7. A. Control; B. Doxorubicin 10nm, C. Paclitaxel 10nm, D. Docetaxel 10nm, combined with gene E. Credit: University of Granada
( University of Granada ) The gene in question is a suicide gene, called "gene E," which leads to the death of tumor cells derived from breast, lung and colon cancer, and prevents their growth. Chemotherapy, radiotherapy and surgery show "limited" results in advanced stages of cancer, so the kind of gene therapy proposed by the scientists of the UGR is a huge breakthrough in cancer treatment.
Around the world, there are more than 1,500 gene therapy trials going on to treat everything from Parkinson's to blindness to clogged arteries. Could the key to healing be in the body's building blocks?
Using a gene-therapy delivery system developed in the laboratory of Inder Verma at the Salk Institute for Biological Studies, an international research team successfully treated two boys from Spain suffering from adrenoleukodystrophy (ALD), the rare, inherited disease that was the focus of the Hollywood film "Lorenzo's Oil." The genetic disorder, in which the fatty insulation of nerve cells ...
AMSTERDAM, November 18 /PRNewswire-FirstCall/ -- - Glybera(R) Clinical Data Presented at Meeting of American Heart Association Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive.
( The Mount Sinai Hospital / Mount Sinai School of Medicine ) Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the US.
Researchers are preparing for the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study, the first multicenter neurosurgical intervention in Alzheimer's research in the U.S., utilizes a viral-based gene transfer system, CERE-110, that makes Nerve Growth Factor (NGF), a naturally occurring protein that helps maintain nerve cell survival in the brain.
